Trigeminal Neuralgia
The most likely diagnosis is trigeminal neuralgia (TN), specifically classical trigeminal neuralgia, which presents as sudden, severe, unilateral, brief stabbing pain in the trigeminal nerve distribution with complete pain-free intervals between attacks.
Clinical Reasoning
This 24-year-old woman's presentation is textbook for trigeminal neuralgia based on the following key features 1:
- Sudden onset, severe, sharp pain - described as "electric shock-like" or "stabbing" in TN
- Brief duration (approximately 1 minute) - TN attacks typically last seconds to minutes
- Unilateral facial distribution (left side) - TN is characteristically unilateral
- Recurrent episodes (3-4 attacks daily for 3 days) - paroxysmal pattern is pathognomonic
- Complete resolution between attacks - asymptomatic intervals are essential for diagnosis
- Pain-free periods - distinguishes TN from continuous facial pain syndromes
The International Association for the Study of Pain defines TN as "sudden usually unilateral severe brief stabbing recurrent episodes of pain in the distribution of one or more branches of the trigeminal nerve" 1.
Age Consideration
While TN typically presents at age 50-60 years 2, it can occur in younger patients. In a 24-year-old, you must rule out secondary causes, particularly:
- Multiple sclerosis - most important consideration in young patients
- Tumors (usually benign) - can compress the trigeminal nerve
- Vascular malformations
Diagnostic Workup
Brain MRI with and without contrast is mandatory 2. This imaging serves two critical purposes:
- Rule out secondary TN - identify MS plaques, tumors, or vascular lesions
- Identify neurovascular compression - determines surgical candidacy if needed
The examination between attacks will typically be normal 1. Look specifically for:
- Light touch-evoked pain in trigeminal distributions
- Trigger zones (areas where minimal stimulation precipitates attacks)
- Any sensory changes (rare in classical TN)
Differential Diagnoses to Exclude
Trigeminal autonomic cephalalgias (SUNA/SUNCT) can mimic TN but have key differences 1:
- More frequent attacks (up to 200 daily vs. 3-4 in this case)
- Autonomic features (tearing, red eye, rhinorrhea, nasal blockage) - absent in this patient
- No refractory period between attacks
- Shorter duration (seconds)
Glossopharyngeal neuralgia has identical pain characteristics but different location (ear, posterior tongue, throat) 1.
Classification
Based on MRI findings, classify as 3:
- Classical TN - if neurovascular compression with morphological changes demonstrated
- Secondary TN - if MS, tumor, or other neurologic disease identified
- Idiopathic TN - if no identifiable cause (occurs in ~50% of cases)
Initial Management
Start carbamazepine immediately - it is the first-line drug of choice with 75% achieving initial symptom control 1, 2. Alternative first-line option is oxcarbazepine, which is equally effective with fewer side effects 1.
Dosing Strategy
- Begin with low doses to minimize side effects
- Titrate upward based on response
- Monitor for dose-dependent adverse effects (dizziness, ataxia, diplopia, hyponatremia)
Second-Line Options
If carbamazepine/oxcarbazepine fails or causes intolerable side effects 1:
- Lamotrigine
- Baclofen
- Gabapentin (with ropivacaine in some protocols)
- Pregabalin
Critical Pitfalls
- Do not delay MRI - missing a tumor or MS in a young patient has serious consequences for morbidity and mortality
- Do not assume classical TN without imaging - secondary causes are more common in younger patients
- Do not use typical analgesics - NSAIDs and opioids are ineffective for TN
- Early neurosurgical referral if medical management fails - delays worsen quality of life significantly 1
When to Refer for Surgery
Consider neurosurgical evaluation if 1:
- Side effects become intolerable
- Pain control is suboptimal despite medication trials
- Patient preference for definitive treatment
Microvascular decompression is the only non-ablative procedure with 70% pain-free at 10 years, though it carries 0.4% mortality and 2-4% hearing loss risk 1.